Menu

Filtros : "Indexado na Base de Dados CAB Abstracts" "2009" Removido: "FO-ODD" Limpar

Filtros

Refine with date range

  • 1

1 - 3 (3 records)

  • Artigo de periodico

    Complement 4 phenotypes and genotypes in Brazilian patients with classical 21-hydroxylase deficiency (2009)

    Guerra-Júnior, G.; Grumach, Anete Sevciovic; Lemos-Marini, S. H. Valente de; Kirschfink, M.; Condino Neto, Antônio; Araújo, M. de; De Mello, M. Palandi

    Source: Clinical and Experimental Immunology. Unidade: ICB

    Assunto: IMUNOLOGIA

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      GUERRA-JÚNIOR, G. et al. Complement 4 phenotypes and genotypes in Brazilian patients with classical 21-hydroxylase deficiency. Clinical and Experimental Immunology, v. 155, n. 2, p. 182-188, 2009Tradução . . Disponível em: https://doi.org/10.1111/j.1365-2249.2008.03838.x. Acesso em: 29 set. 2024.

    • APA

      Guerra-Júnior, G., Grumach, A. S., Lemos-Marini, S. H. V. de, Kirschfink, M., Condino Neto, A., Araújo, M. de, & De Mello, M. P. (2009). Complement 4 phenotypes and genotypes in Brazilian patients with classical 21-hydroxylase deficiency. Clinical and Experimental Immunology, 155( 2), 182-188. doi:10.1111/j.1365-2249.2008.03838.x

    • NLM

      Guerra-Júnior G, Grumach AS, Lemos-Marini SHV de, Kirschfink M, Condino Neto A, Araújo M de, De Mello MP. Complement 4 phenotypes and genotypes in Brazilian patients with classical 21-hydroxylase deficiency [Internet]. Clinical and Experimental Immunology. 2009 ; 155( 2): 182-188.[citado 2024 set. 29 ] Available from: https://doi.org/10.1111/j.1365-2249.2008.03838.x

    • Vancouver

      Guerra-Júnior G, Grumach AS, Lemos-Marini SHV de, Kirschfink M, Condino Neto A, Araújo M de, De Mello MP. Complement 4 phenotypes and genotypes in Brazilian patients with classical 21-hydroxylase deficiency [Internet]. Clinical and Experimental Immunology. 2009 ; 155( 2): 182-188.[citado 2024 set. 29 ] Available from: https://doi.org/10.1111/j.1365-2249.2008.03838.x

  • Artigo de periodico

    Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole (2009)

    Buschini, Annamaria; Ferrarini, Lisa; Galati, Serena; Lazzaretti, Mirca; Mussi, Francesca; Albuquerque, Cristina Northfleet de ; Zucchi, Tânia Maria Araújo Domingues; Poli, Paola

    Source: Journal of Parasitology Research. Unidades: FCF, ICB

    Assunto: PARASITOLOGIA

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      BUSCHINI, Annamaria et al. Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole. Journal of Parasitology Research, 2009Tradução . . Disponível em: https://doi.org/10.1155/2009/463575. Acesso em: 29 set. 2024.

    • APA

      Buschini, A., Ferrarini, L., Galati, S., Lazzaretti, M., Mussi, F., Albuquerque, C. N. de, et al. (2009). Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole. Journal of Parasitology Research. doi:10.1155/2009/463575

    • NLM

      Buschini A, Ferrarini L, Galati S, Lazzaretti M, Mussi F, Albuquerque CN de, Zucchi TMAD, Poli P. Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole [Internet]. Journal of Parasitology Research. 2009 ;[citado 2024 set. 29 ] Available from: https://doi.org/10.1155/2009/463575

    • Vancouver

      Buschini A, Ferrarini L, Galati S, Lazzaretti M, Mussi F, Albuquerque CN de, Zucchi TMAD, Poli P. Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole [Internet]. Journal of Parasitology Research. 2009 ;[citado 2024 set. 29 ] Available from: https://doi.org/10.1155/2009/463575

  • Artigo de periodico

    Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease (2009)

    Schaeffer, Evelin L.; Forlenza, Orestes V.; Gattaz, Wagner F.

    Source: Psychopharmacology. Unidade: FM

    Subjects: COGNIÇÃO (TREINAMENTO), TRANSTORNOS COGNITIVOS (PREVENÇÃO E CONTROLE), DOENÇA DE ALZHEIMER, FOSFOLIPASES A (ATIVIDADE)

    Acesso à fonteAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SCHAEFFER, Evelin L. e FORLENZA, Orestes V. e GATTAZ, Wagner F. Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Psychopharmacology, v. 202, n. 1-3, p. 37-51, 2009Tradução . . Disponível em: https://doi.org/10.1007/s00213-008-1351-0. Acesso em: 29 set. 2024.

    • APA

      Schaeffer, E. L., Forlenza, O. V., & Gattaz, W. F. (2009). Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Psychopharmacology, 202( 1-3), 37-51. doi:10.1007/s00213-008-1351-0

    • NLM

      Schaeffer EL, Forlenza OV, Gattaz WF. Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease [Internet]. Psychopharmacology. 2009 ; 202( 1-3): 37-51.[citado 2024 set. 29 ] Available from: https://doi.org/10.1007/s00213-008-1351-0

    • Vancouver

      Schaeffer EL, Forlenza OV, Gattaz WF. Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease [Internet]. Psychopharmacology. 2009 ; 202( 1-3): 37-51.[citado 2024 set. 29 ] Available from: https://doi.org/10.1007/s00213-008-1351-0
  • 1

1 - 3 (3 records)

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2024